{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:14Z","timestamp":1790188154824,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470594"],"award-info":[{"award-number":["81470594"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570859"],"award-info":[{"award-number":["81570859"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670878"],"award-info":[{"award-number":["81670878"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.biopha.2018.08.092","type":"journal-article","created":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T06:28:55Z","timestamp":1535178535000},"page":"1056-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy"],"prefix":"10.1016","volume":"107","author":[{"given":"Xiao-Pei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Guo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-Di","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2018.08.092_bib0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular neovascularization","volume":"91","author":"Campochiaro","year":"2013","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.092_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog. Retin. Eye Res."},{"issue":"42","key":"10.1016\/j.biopha.2018.08.092_bib0015","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1038\/sj.onc.1206773","article-title":"Ocular neovascularization: a valuable model system","volume":"22","author":"Campochiaro","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2018.08.092_bib0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10456-007-9069-x","article-title":"Combination therapy for the treatment of ocular neovascularization","volume":"10","author":"Bradley","year":"2007","journal-title":"Angiogenesis"},{"issue":"8","key":"10.1016\/j.biopha.2018.08.092_bib0025","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2174\/156652409789712783","article-title":"Current molecular understanding and future treatment strategies for pathologic ocular neovascularization","volume":"9","author":"Tolentino","year":"2009","journal-title":"Curr. Mol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.08.092_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","article-title":"The role of vascular endothelial growth factor in ocular health and disease","volume":"25","author":"Adamis","year":"2005","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.biopha.2018.08.092_bib0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2018.08.092_bib0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.med.60.041807.132435","article-title":"Evolving treatment of advanced colon cancer","volume":"60","author":"Segal","year":"2009","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.08.092_bib0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"issue":"5","key":"10.1016\/j.biopha.2018.08.092_bib0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.biopha.2018.08.092_bib0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.biopha.2018.08.092_bib0060","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.biopha.2018.08.092_bib0065","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"issue":"1-2","key":"10.1016\/j.biopha.2018.08.092_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.05.003","article-title":"Nanotechnology: what it can do for drug delivery","volume":"120","author":"Park","year":"2007","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.biopha.2018.08.092_bib0075","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"issue":"2","key":"10.1016\/j.biopha.2018.08.092_bib0080","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.biopha.2018.08.092_bib0085","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s11051-012-1316-4","article-title":"Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system","volume":"14","author":"Locatelli","year":"2012","journal-title":"J. Nanopart. Res."},{"issue":"4","key":"10.1016\/j.biopha.2018.08.092_bib0090","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/erm.09.15","article-title":"Current advances in research and clinical applications of PLGA-based nanotechnology","volume":"9","author":"L\u00fc","year":"2009","journal-title":"Exp. Rev. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.biopha.2018.08.092_bib0095","first-page":"3867","article-title":"Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy","volume":"29","author":"Mukerjee","year":"2009","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2018.08.092_bib0100","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.1016\/j.actbio.2013.06.034","article-title":"Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy","volume":"9","author":"Tao","year":"2013","journal-title":"Acta Biomater."},{"issue":"15","key":"10.1016\/j.biopha.2018.08.092_bib0105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.addr.2008.08.003","article-title":"Nanoparticles in photodynamic therapy: an emerging paradigm","volume":"60","author":"Chatterjee","year":"2008","journal-title":"Adv. Drug Deliver. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2018.08.092_bib0110","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomed. Mater. Res. A."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.092_bib0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0142-9612(00)00178-2","article-title":"Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction\/evaporation method","volume":"22","author":"Yang","year":"2001","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.biopha.2018.08.092_bib0120","doi-asserted-by":"crossref","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","article-title":"Role of vascular endothelial growth factor in regulation of physiological angiogenesis","volume":"280","author":"Ferrara","year":"2001","journal-title":"Am. J. Physiol."},{"issue":"12","key":"10.1016\/j.biopha.2018.08.092_bib0125","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1167\/iovs.11-7255","article-title":"Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects","volume":"52","author":"Su","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7070","key":"10.1016\/j.biopha.2018.08.092_bib0130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nature04482","article-title":"Retinal angiogenesis in development and disease","volume":"438","author":"Gariano","year":"2005","journal-title":"Nature"},{"issue":"3-4","key":"10.1016\/j.biopha.2018.08.092_bib0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2013.07.014","article-title":"The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments","volume":"50","author":"Varshochian","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2018.08.092_bib0140","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.3390\/ijms12118288","article-title":"Nanotechnology and nanotoxicology in retinopathy","volume":"12","author":"Jo","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"8-9","key":"10.1016\/j.biopha.2018.08.092_bib0145","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.progpolymsci.2007.05.017","article-title":"Biodegradable polymers as biomaterials","volume":"32","author":"Nair","year":"2007","journal-title":"Prog. Polym. Sci."},{"issue":"7347","key":"10.1016\/j.biopha.2018.08.092_bib0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2018.08.092_bib0155","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"6","key":"10.1016\/j.biopha.2018.08.092_bib0160","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.biopha.2018.08.092_bib0165","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.biopha.2018.08.092_bib0170","first-page":"603","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"New England J. Med. Surg. Collat. Branches Sci."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218345049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218345049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:23:00Z","timestamp":1766024580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218345049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":34,"alternative-id":["S0753332218345049"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.092","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}